Introduction {#Sec1}
============

*Acinetobacter baumannii* is an important human nosocomial pathogen, referred to an ESKAPE pathogen (*Enterococcus faecium*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Acinetobacter baumannii*, *Pseudomonas aeruginosa* and *Enterobacter* species), harbouring multiple genes associated with antimicrobial resistance \[[@CR1]\]. Hospital-acquired infections caused by *A. baumannii* often lead to increased morbidity and mortality \[[@CR2]\], due to limited antibiotic therapies. Antibiotics of last resort, such as tigecycline and colistin, are increasingly used, but with the emergence of resistance to these drugs, clinicians may resort to unorthodox antibiotic combination therapies \[[@CR3]\].

Potential alternatives to antibiotics includes metal nanoparticles and plant-derived compounds such as polyphenols. Polyphenols play an important role in plant defence systems against microbial pathogens \[[@CR4]\]. Several studies have shown that polyphenols have antimicrobial activity against human and animal pathogens including bacteria, fungi and viruses \[[@CR5]--[@CR8]\].

Synergistic activity between polyphenols and some traditional antibiotics has been observed against multidrug-resistant (MDR) bacteria \[[@CR9]--[@CR12]\]. Similarly, combinations of polyphenols have been shown to be effective at inhibiting bacterial growth in vitro, with higher concentrations also leading to bacterial cell death \[[@CR13]--[@CR15]\]. However, no data exist on the in vivo activity of polyphenol combinations. A model in which the in vivo efficacy of polyphenol combinations can rapidly be determined, is the greater wax moth larvae, *Galleria mellonella*. This Lepidopteran is now a popular model for experimental bacteraemia studies, due to its high throughput, lack of Home Office restrictions and an innate immune system comparable with that of mammals \[[@CR16]\]. Until recently, one disadvantage of the *G. mellonella* model was the lack of standardisation between suppliers, leading to high standard error and poor reproducibility across assays, making statistical analysis difficult. However, a standardised model, with controlled age, size and food supply, is now available. Using the TruLarv *G. mellonella* model (Biosystems Technology, Exeter, UK), highly reproducible data can be produced.

The aim of this study was to determine the in vitro kill kinetics and the in vivo toxicity and efficacy of theaflavin--epicatechin combinations against MDR strains of *A. baumannii* in the TruLarv *G. mellonella* model of infection.

Methods {#Sec2}
=======

Chemicals, Media and Bacterial Isolates {#Sec3}
---------------------------------------

Epicatechin (≥90%) powder, Luria broth base and Mueller--Hinton 2 agar/broth were purchased from Sigma-Aldrich (Dorset, UK). Theaflavin (≥95%) was donated by Unilever (Bedford, UK). Type strain *A. baumannii* ATCC 19606 was purchased from Pro-Lab Diagnostics (Wirral, UK). Clinical isolates (*n* = 6) \[[@CR17]\] were obtained from the Royal London Hospital (Whitechapel, UK) where they were identified via standard biochemical methods and Maldi-TOF. Isolates represent major clonal strains from the United Kingdom. All isolates were stored long term on cryobeads at −80 °C.

Antimicrobial Susceptibility Testing {#Sec4}
------------------------------------

Minimum inhibitory concentrations (MICs) of theaflavin and epicatechin were determined alone and in combination against all 6 MDR isolates, performed in 96-well microtitre plates using Mueller--Hinton 2 cation-adjusted broth. Checkerboard assays were used with twofold decreasing concentrations of theaflavin (512--0 mg/L) and epicatechin (1024--0 mg/L) with a bacterial inoculum of 10^5^ colony forming units (CFU) per mL. Plates were incubated at 37 °C for 24 h. Where the MIC was not determined, the dilution above the maximum dose was used in calculating the fractional inhibitory concentration indices (FICIs). Fractional inhibitory concentration indices were calculated using the following equation, as previously described \[[@CR18]\]: FICI = FIC of A (MIC of antibiotic A in combination with antibiotic B/MIC of antibiotic A alone) + FIC of B (MIC of antibiotic B in combination with antibiotic A/MIC of antibiotic B alone). FICI values of ≤0.5 suggest a synergistic interaction, \>0.5--1.0 as an additive effect, \>1.0 to \<4 as indifference and a value of ≥4.0 was classed as an antagonistic effect \[[@CR19]\]. All experiments were performed in triplicate, on three separate occasions.

Kill-Kinetic Assays {#Sec5}
-------------------

Kill-kinetic assays were performed using strains AB12, AB16, AB210 and the ATCC 19606 type strain. Isolates AB12, AB16 and AB210 were used as they represent the important clonal groups in the UK \[[@CR17], [@CR20]\]. In brief, a 1/1000 dilution of an 18-h bacterial culture, equating to approximately 10^6^ CFU/mL, was used as the starting inoculum for each strain. Antimicrobials were added to individual cultures at the following final concentrations: theaflavin (0.5 mg/mL), epicatechin (0.5 mg/mL) and theaflavin and epicatechin combination (0.5 + 0.5 mg/mL). Cultures were incubated at 37 °C under continuous agitation (225 rpm) for 24 h. At set time intervals of 0, 2, 4, 6 and 24 h post-inoculation, 100-μL samples were collected, serially diluted and plated onto Mueller--Hinton 2 agar. Viable counts were performed after incubation at 37 °C for 20 h.

In vivo Toxicity in *Galleria mellonella* {#Sec6}
-----------------------------------------

In vivo testing was conducted using the *Galleria mellonella* invertebrate model (TruLarv™, Biosystems Technology, Exeter, UK). In brief, ten larvae were injected via the left proleg with 10, 20, 40, 60, 80, 100, 200, 400, 600, 800 or 1000 mg/kg doses of theaflavin or epicatechin, freshly prepared in phosphate-buffered saline (PBS). PBS was used in the control injections. Larvae were incubated at 37 °C for 96 h and were observed every 24 h. The degree of melanisation and mortality was recorded at each observational time point. This article does not contain any new studies with human or animal subjects performed by any of the authors.

Inoculum Testing {#Sec7}
----------------

To determine the optimum inoculum for staggered larval killing (c. 80% mortality of larvae at 96 h post-inoculation), an inoculum test was performed. In brief, 16 h cultures of *A. baumannii* strains AB12, AB16, AB210 and the type strain ATCC 19606 in LB broth were washed in PBS before being serially diluted. Colony-forming units were determined after plating the dilutions on nutrient agar and incubating at 37 °C for 24 h. Ten *G. mellonella* larvae were infected with the 16 h culture dilutions, equating to 10^3^, 10^4^, 10^5^ and 10^6^ CFU/larvae, via a 10 µL injection into the left proleg. Larvae were incubated at 37 °C and scored for survival (live/dead) at 0, 24, 48, 72 and 96 h.

Treatment Assays {#Sec8}
----------------

Sixteen larvae were infected with 10^5^ CFU/larvae of ATCC 19606, AB12, AB16 or AB210. Thirty minutes post-inoculation, a second injection was administered of theaflavin (20 mg/kg in PBS), epicatechin (40 mg/kg in PBS), a combination of theaflavin and epicatechin (20 + 40 mg/kg) or PBS. Larvae were incubated at 37 °C in Petri dishes lined with Whatman™ filter paper and scored for survival (live/dead) at 0, 24, 48, 72 and 96 h. All insects were also scored for melanisation over 96 h. Melanisation was quantified based on a reversed scoring method \[[@CR16]\], whereby a score of 4 indicated total melanisation of the larvae, 2 equalled melanin spots over the larvae, 1 equalled discolouration of the tail and a score of 0 equalled no melanisation. All in vivo experiments were carried out in triplicate on 3 separate occasions.

Statistical Analyses {#Sec9}
--------------------

Time--kill curves (CFU/mL vs. time) and survival curves were plotted using GraphPad Prism 7.0 software. Synergy was defined as bactericidal activity (≥2 log~10~ difference in CFU/mL) of the combination compared to the single agent after 24 h incubation. Unpaired Student's *t* tests were performed to check for significant variance.

Survival curves were analysed using the log rank test with a *p* value of ≤0.05 indicating statistical significance. At the 96-h time-point, percentage survival of all antibiotic-treated larvae was calculated using combined data from replicate experiments. One-tailed, unpaired *t* tests were used to compare mean values, as described previously \[[@CR21]\].

Results {#Sec10}
=======

Broth microtitre testing revealed high MICs for both theaflavin and epicatechin (256--512 and 1024--2048 mg/L, respectively) for all *A. baumannii* isolates tested (Table [1](#Tab1){ref-type="table"}). However, when used in combination, MICs were significantly (*p* ≤ 0.05) reduced for both theaflavin and epicatechin (16--64 and 16--512 mg/L, respectively). The FICs indicate synergistic activity of the theaflavin and epicatechin combination (≤0.5).Table 1Mean minimum inhibitory concentrations and fractional inhibitory concentrations for theaflavin (TF) and epicatechin (EC) alone and in combination versus *Acinetobacter baumannii* isolates usedIsolatesDescriptionMIC (mg/L)MIC in combination (mg/L)FICITFECTFEC*A. baumannii* NCTC 19606Type strain512204864320.14*A. baumannii* AB12Clinical isolate of PFGE-defined UK lineage: 'South East clone'512204816160.04*A. baumannii* AB16Clinical isolate of PFGE-defined UK lineage: 'OXA-23 clone 2'2561024641280.38*A. baumannii* AB184Clinical isolate of PFGE-defined UK lineage: 'T'2561024642560.50*A. baumannii* AB186Clinical isolate of PFGE-defined UK lineage: 'Burn'5122048165120.28*A. baumannii* AB210Clinical isolate of PFGE-defined UK lineage: 'OXA-23 clone 1'512204832160.07*A. baumannii* AB211Clinical isolate of PFGE-defined UK lineage: 'OXA-23 clone 1'2561024642560.50

Data from the kill-kinetic assays showed that *A. baumannii* exposed to epicatechin alone regrew (2--3 log~10~ CFU/mL) after 24 h (Fig. [1](#Fig1){ref-type="fig"}). No significant difference between EC and the no-drug control was observed. In 2/3 isolates tested, theaflavin produced bacteriostatic activity, with CFU/mL maintained over 24 h. However, with AB210, regrowth was observed after 4 h. The combination of theaflavin and epicatechin had a greater impact than any agent alone on the kill kinetics of *A. baumannii.* For ATCC 19606, a \>2 log~10~ reduction in CFU/mL at 24 h was observed. However, significant (*p* ≤ 0.05) differences were observed between the combination and monotherapy alone against AB12, AB16 and AB210, with a \>3 log~10~ reduction in CFU/mL at 24 h, indicating synergy and bactericidal activity.Fig. 1Kill kinetics of epicatechin (EC), theaflavin (TF), EC + TF combinations and a Mueller--Hinton control versus multidrug-resistant *Acinetobacter baumannii* strains. **a** ATCC 19696, **b** AB12, **c** AB16 and **d** AB210

Results from the in vivo toxicity testing showed no insect deaths after injection with any of the polyphenols at any concentration over 96 h. No melanisation was observed in any insect, indicating the absence of observable, phenotypic toxicological effects of theaflavin and epicatechin in *Galleria mellonella.*

Data from the in vivo treatment assays suggest that monotherapy with theaflavin or epicatechin affords greater larval survival than PBS over 96 h, with overall survival rates of 52% \[±14 standard deviation percentage points (pp)\] and 44 (±22 pp), respectively (Fig. [2](#Fig2){ref-type="fig"}). However, when treated with the theaflavin--epicatechin combination, larval survival rates significantly increased to 86% (±17 pp) (*p* ≤ 0.05).Fig. 2Survival curves for *Galleria mellonella* infected with 10^4^ CFU/larvae of multidrug-resistant *A. baumannii* strains. **a** ATCC 19696, **b** AB12, **c** AB16 and **d** AB210, treated with phosphate-buffered saline (PBS), epicatechin (EC), theaflavin (TF) or EC + TF combinations

High levels of morbidity were observed over 96 h in *A. baumannii*-infected larvae, 'treated' with PBS alone (Fig. [3](#Fig3){ref-type="fig"}). Medium to high melanisation scores were recorded at 96 h for infected larvae treated with theaflavin or epicatechin monotherapy. Low melanisation scores were observed for the theaflavin--epicatechin combination.Fig. 3Effect of treatments of phosphate buffered saline (PBS), epicatechin (EC), theaflavin (TF) or EC + TF combination on morbidity (melanisation) over 96 h in *Galleria mellonella* infected with 10^4^ CFU/larva *Acinetobacter baumannii.* **a** ATCC 19696, **b** AB12, **c** AB16 and **d** AB210, with higher melanisation scores indicating greater morbidity

Discussion {#Sec11}
==========

The high MICs for theaflavin and epicatechin were not unexpected and are likely due to non-specific binding and/or degradation/dimerization of the polyphenols, which have been previously highlighted as factors reducing activity \[[@CR22], [@CR23]\].

Data from the time--kill assays clearly demonstrated that the theaflavin--epicatechin combination was not only synergistic but also bactericidal. This confirms previous kill-kinetic studies using polyphenolics, which also showed that combinations of polyphenols are synergistic and significantly reduce CFU/mL \[[@CR24]\].

The lack of toxicity, at high administrated concentrations, may provide greater support for the use of polyphenols as treatments for bacterial infections. However, these observations might be due, in part, to the natural diet of *G. mellonella* larvae, which includes bee honeycomb that is naturally abundant in phenolic and polyphenolic compounds \[[@CR25]\]. Therefore, *G. mellonella* larvae may have evolved to tolerate such compounds. Potential toxicity should be further assessed in mammalian models.

Data from the in vivo treatment assays demonstrated that monotherapy with either theaflavin or epicatechin was more efficacious than 'treatment' with PBS alone. Previous studies using *Caenorhabditis elegans* \[[@CR26]\] found that monotherapy with epigallocatechin gallate (EGCG) increased survival rates of *Escherichia coli* infected nematodes by 28.9--76% compared with uninfected controls. However, the *C. elegans* model is incubated at 25 °C and not 37 °C (as with *G. mellonella*) and infection/treatment relies on the animal's ability to consume the inoculum/antimicrobial. This might have had an impact on the growth of the bacteria and therefore the susceptibility to EGCG. Treatment with the polyphenol combination was significantly more effective at preventing larval death than monotherapy. These data support the use of combination therapies and clearly demonstrate that the theaflavin--epicatechin combination is an effective treatment in an invertebrate in vivo model of infection.

High melanisation scores are indicative of a substantial immune response. The medium to high melanisation scores of larvae treated with theaflavin--epicatechin indicate that monotherapy is not adequate for reducing morbidity. A significantly reduced phenotypically detected immune response was observed in larvae treated with the theaflavin--epicatechin combination. This indicates that the combination reduced overall morbidity and mortality, compared with monotherapy. Further studies using mammalian models are now warranted.

The number of clinical isolates used, although representative of epidemic clonal groups in the UK, was relatively small and is thus a limitation of this work. Another limitation of note is the use of an invertebrate model of infection, which lacks an adaptive immune response and the detoxification systems found in mammals.

Conclusion {#Sec12}
==========

Polyphenol combinations show great potential for the treatment of infections caused by MDR *A. baumannii.* Significant increases in survival were observed when *A. baumannii*-infected larvae were treated with a theaflavin--epicatechin combination, compared with monotherapy. To our knowledge, this is the first study to unequivocally demonstrate antibacterial activity of polyphenols in *G. mellonella* and the first in vivo report where combinations of polyphenols have showed antibacterial activity against bacterial pathogens.
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